Prof. Xiaoli Liao 廖小莉
Chief Physician, Professor
Department of Digestive Oncology, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of primary liver cancer, gastric cancer, colorectal cancer, pancreatic cancer, esophageal cancer, nasopharyngeal carcinoma, lung cancer, breast cancer, and lymphoma.
Dr. Liao holds a medical doctorate and serves as Professor and Chief Physician. Since graduating in 2002, Dr. Liao has worked in clinical oncology, research, and teaching. Dr. Liao leads the Department of Digestive Oncology at Guangxi Medical University Cancer Hospital and supervises master's students. Dr. Liao has published over 20 papers and co-authored two monographs.
Professional roles
- Member, Guangxi Branch of the Chinese Medical Association
- Member, Clinical Application Committee of Pharmaceutical Biotechnology, China Medicine Biotech Association
- Member, Tumor Drug Clinical Research Committee, Guangxi Anti-Cancer Association
- Member, Precision Medicine Branch, Guangxi Medical Association
Name order: in Chinese the family name comes first (Liao Xiaoli). Papers usually list the name as Xiaoli Liao or Liao X.
Selected publications
9 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2024 (senior author): Nomogram for predicting overall survival of metastatic pancreatic cancer patients based on HBV infection and inflammatory-nutritional biomarkers. PubMed 39026969
- Pathol Oncol Res, 2022 (first author): Prognostic value of long non-coding RNA MALAT1 in hepatocellular carcinoma: A study based on multi-omics analysis and RT-PCR validation. PubMed 36685103
- Front Oncol, 2022 (senior author): Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1). PubMed 35847852
- Pathol Oncol Res, 2022 (senior author): Holliday Cross-Recognition Protein HJURP: Association With the Tumor Microenvironment in Hepatocellular Carcinoma and With Patient Prognosis. PubMed 35783358
- Onco Targets Ther, 2020 (first author): Expression and Clinical Significance of ERCC1 and XPF in Human Hepatocellular Carcinoma. PubMed 32099408
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion